IR@PKUHSC  > 北京大学第三临床医学院
学科主题临床医学
Siltuximab for multicentric Castleman′s disease: a randomised, double-blind, placebo-controlled trial
van Rhee, Frits1; Wong, Raymond S.2; Munshi, Nikhil3; Rossi, Jean-Francois4; Ke, Xiao-Yan5; Fossa, Alexander6; Simpson, David7; Capra, Marcelo8; Liu, Ting9; Hsieh, Ruey Kuen10; Goh, Yeow Tee11; Zhu, Jun12; Cho, Seok-Goo13; Ren, Hanyun14; Cavet, James15,16; Bandekar, Rajesh17; Rothman, Margaret18; Puchalski, Thomas A.17; Reddy, Manjula17; van de Velde, Helgi19; Vermeulen, Jessica20; Casper, Corey21
刊名LANCET ONCOLOGY
2014-08-01
DOI10.1016/S1470-2045(14)70319-5
15期:9页:966-974
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]ANTI-INTERLEUKIN-6 MONOCLONAL-ANTIBODY ; LYMPH-NODE HYPERPLASIA ; RITUXIMAB ; SPECTRUM
英文摘要

Background Multicentric Castleman′s disease is a rare lymphoproliferative disorder driven by dysregulated production of interleukin 6. No randomised trials have been done to establish the best treatment for the disease. We assessed the safety and efficacy of siltuximab-a chimeric monoclonal antibody against interleukin 6-in HIV-negative patients with multicentric Castleman′s disease.

Methods We did this randomised, double-blind, placebo-controlled study at 38 hospitals in 19 countries worldwide. We enrolled HIV-negative and human herpesvirus-8-seronegative patients with symptomatic multicentric Castleman′s disease. Treatment allocation was randomised with a computer-generated list, with block size six, and stratification by baseline corticosteroid use. Patients and investigators were masked to treatment allocation. Patients were randomly assigned (2: 1) to siltuximab (11 mg/kg intravenous infusion every 3 weeks) or placebo; all patients also received best supportive care. Patients continued treatment until treatment failure. The primary endpoint was durable tumour and symptomatic response for at least 18 weeks for the intention-to-treat population. Enrolment has been completed. The study is registered with ClinicalTrials.gov, number NCT01024036.

Findings We screened 140 patients, 79 of whom were randomly assigned to siltuximab (n=53) or placebo (n=26). Durable tumour and symptomatic responses occurred in 18 (34%) of 53 patients in the siltuximab group and none of 26 in the placebo group (difference 34 0%, 95% CI 11.1-54.8, p=0.0012). The incidence of grade 3 or more adverse events (25 [47%]vs 14 [54%]) and serious adverse events (12 [23%] vs five [19%]) was similar in each group despite longer median treatment duration with siltuximab than with placebo (375 days [range 1-1031] vs 152 days [23-666]). The most common grade 3 or higher were fatigue (five vs one), night sweats (four vs one), and anaemia (one vs three). Three (6%) of 53 patients had serious adverse events judged reasonably related to siltuximab (lower respiratory tract infection, anaphylactic reaction, sepsis).

Interpretation Siltuximab plus best supportive care was superior to best supportive care alone for patients with symptomatic multicentric Castleman′s disease and well tolerated with prolonged exposure. Siltuximab is an important new treatment option for this disease.

语种英语
WOS记录号WOS:000341311600041
资助机构Janssen Research Development
引用统计
被引频次:112[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/65401
专题北京大学第三临床医学院
北京大学第一临床医学院_血液内科
北京大学临床肿瘤学院_淋巴肿瘤内科
作者单位1.Peking Univ, Hosp 3, Beijing 100871, Peoples R China
2.Oslo Univ Hosp, Oslo, Norway
3.North Shore Hosp, Takapuna Auckland, New Zealand
4.Hosp Mae de Deus, Porto Alegre, RS, Brazil
5.Sichuan Univ, West China Hosp, Chengdu 610064, Peoples R China
6.Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA
7.Chinese Univ Hong Kong, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China
8.Dana Farber Canc Inst, Boston, MA 02115 USA
9.CHU Montpellier, Hop St Eloi, Montpellier, France
10.Mackay Mem Hosp, Taipei, Taiwan
11.Singapore Gen Hosp, Singapore, Singapore
12.Beijing Canc Hosp, Beijing, Peoples R China
13.Seoul St Marys Hosp, Seoul, South Korea
14.Peking Univ, Hosp 1, Beijing 100871, Peoples R China
15.Christie NHS Fdn Trust, Manchester, Lancs, England
16.Univ Manchester, Manchester, Lancs, England
17.Janssen Res & Dev, Spring House, PA USA
18.Janssen Res & Dev, Washington, GA USA
19.Janssen Res & Dev, Beerse, Belgium
20.Janssen Res & Dev, Leiden, Netherlands
21.Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
推荐引用方式
GB/T 7714
van Rhee, Frits,Wong, Raymond S.,Munshi, Nikhil,et al. Siltuximab for multicentric Castleman′s disease: a randomised, double-blind, placebo-controlled trial[J]. LANCET ONCOLOGY,2014,15(9):966-974.
APA van Rhee, Frits.,Wong, Raymond S..,Munshi, Nikhil.,Rossi, Jean-Francois.,Ke, Xiao-Yan.,...&Casper, Corey.(2014).Siltuximab for multicentric Castleman′s disease: a randomised, double-blind, placebo-controlled trial.LANCET ONCOLOGY,15(9),966-974.
MLA van Rhee, Frits,et al."Siltuximab for multicentric Castleman′s disease: a randomised, double-blind, placebo-controlled trial".LANCET ONCOLOGY 15.9(2014):966-974.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[van Rhee, Frits]的文章
[Wong, Raymond S.]的文章
[Munshi, Nikhil]的文章
百度学术
百度学术中相似的文章
[van Rhee, Frits]的文章
[Wong, Raymond S.]的文章
[Munshi, Nikhil]的文章
必应学术
必应学术中相似的文章
[van Rhee, Frits]的文章
[Wong, Raymond S.]的文章
[Munshi, Nikhil]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。